Literature DB >> 10814710

Biochemical and structural analysis of missense mutations in N-acetylgalactosamine-6-sulfate sulfatase causing mucopolysaccharidosis IVA phenotypes.

K Sukegawa1, H Nakamura, Z Kato, S Tomatsu, A M Montaño, T Fukao, G Toietta, P Tortora, T Orii, N Kondo.   

Abstract

Mucopolysaccharidosis IVA (MPS IVA; OMIM#253000), a lysosomal storage disorder caused by a deficiency of N -acetylgalactosamine-6-sulfate sulfatase (GALNS), has variable clinical phenotypes. To date we have identified 65 missense mutations in the GALNS gene from MPS IVA patients, but the correlation between genotype and phenotype has remained unclear. We studied 17 missense mutations using biochemical approaches and 32 missense mutations, using structural analyses. Fifteen missense mutations and two newly engineered active site mutations (C79S, C79T) were characterized by transient expression analysis. Mutant proteins, except for C79S and C79T, were destabilized and detected as insoluble precursor forms while the C79S and C79T mutants were of a soluble mature size. Mutants found in the severe phenotype had no activity. Mutants found in the mild phenotype had a considerable residual activity (1.3-13.3% of wild-type GALNS activity). Sulfatases, including GALNS, are members of a highly conserved gene family sharing an extensive sequence homology. Thus, a tertiary structural model of human GALNS was constructed from the X-ray crystal structure of N -acetylgalacto-samine-4-sulfatase and arylsulfatase A, using homology modeling, and 32 missense mutations were investigated. Consequently, we propose that there are at least three different reasons for the severe phenotype: (i) destruction of the hydrophobic core or modification of the packing; (ii) removal of a salt bridge to destabilize the entire conformation; (iii) modification of the active site. In contrast, mild mutations were mostly located on the surface of the GALNS protein. These studies shed further light on the genotype-phenotype correlation of MPS IVA and structure-function relationship in the sulfatase family.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10814710     DOI: 10.1093/hmg/9.9.1283

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  22 in total

Review 1.  Mucopolysaccharidosis IVA and glycosaminoglycans.

Authors:  Shaukat Khan; Carlos J Alméciga-Díaz; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-11-29       Impact factor: 4.797

2.  Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome.

Authors:  Angela C Sosa; Barbara Kariuki; Qi Gan; Alan P Knutsen; Clifford J Bellone; Miguel A Guzmán; Luis A Barrera; Shunji Tomatsu; Anil K Chauhan; Eric Armbrecht; Adriana M Montaño
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

3.  Mutational and structural analysis of Japanese patients with mucopolysaccharidosis type II.

Authors:  Tomomi Kato; Zenichiro Kato; Izumi Kuratsubo; Noboru Tanaka; Tabito Ishigami; Jun-Ichi Kajihara; Kazuko Sukegawa-Hayasaka; Koji Orii; Koji Isogai; Toshiyuki Fukao; Nobuyuki Shimozawa; Tadao Orii; Naomi Kondo; Yasuyuki Suzuki
Journal:  J Hum Genet       Date:  2005-08-30       Impact factor: 3.172

4.  Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations.

Authors:  Laura M Pollard; Julie R Jones; Tim C Wood
Journal:  J Inherit Metab Dis       Date:  2012-09-14       Impact factor: 4.982

5.  Structure-Function Relationships of LDL Receptor Missense Mutations Using Homology Modeling.

Authors:  Sureerut Porntadavity; Nutjaree Jeenduang
Journal:  Protein J       Date:  2019-08       Impact factor: 2.371

6.  Effect of 'attenuated' mutations in mucopolysaccharidosis IVA on molecular phenotypes of N-acetylgalactosamine-6-sulfate sulfatase.

Authors:  A M Montaño; K Sukegawa; Z Kato; R Carrozzo; P Di Natale; E Christensen; K O Orii; T Orii; N Kondo; S Tomatsu
Journal:  J Inherit Metab Dis       Date:  2007-09-17       Impact factor: 4.982

7.  Mucopolysaccharidosis IVA: characterization of a common mutation found in Finnish patients with attenuated phenotype.

Authors:  Adriana Maria Montaño; Ilkka Kaitila; Kazuko Sukegawa; Shunji Tomatsu; Zenichiro Kato; Haruki Nakamura; Seiji Fukuda; Tadao Orii; Naomi Kondo
Journal:  Hum Genet       Date:  2003-04-30       Impact factor: 4.132

8.  Bromocriptine as a Novel Pharmacological Chaperone for Mucopolysaccharidosis IV A.

Authors:  Sergio Olarte-Avellaneda; Jacobo Cepeda Del Castillo; Andrés Felipe Rojas-Rodriguez; Oscar Sánchez; Alexander Rodríguez-López; Diego A Suárez García; Luz Mary Salazar Pulido; Carlos J Alméciga-Díaz
Journal:  ACS Med Chem Lett       Date:  2020-06-24       Impact factor: 4.345

9.  Identification of a common mutation in mucopolysaccharidosis IVA: correlation among genotype, phenotype, and keratan sulfate.

Authors:  Shunji Tomatsu; Tatiana Dieter; Ida V Schwartz; Piedad Sarmient; Roberto Giugliani; Luis A Barrera; Norberto Guelbert; Raquel Kremer; Gabriela M Repetto; Monica A Gutierrez; Tatsuo Nishioka; Olga Peña Serrato; Adriana Maria Montaño; Seiji Yamaguchi; Akihiko Noguchi
Journal:  J Hum Genet       Date:  2004-08-11       Impact factor: 3.172

10.  Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype-phenotype correlation for Morquio A.

Authors:  Sergio Olarte-Avellaneda; Alexander Rodríguez-López; Carlos Javier Alméciga-Díaz; Luis Alejandro Barrera
Journal:  Mol Biol Rep       Date:  2014-10-07       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.